| 000 | 01582cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030601.0 | ||
| 008 | 120307s2011 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.08.08.Ph.D.2011.Al.P | ||
| 100 | 0 | _aAly Ahmed Abdelbary | |
| 245 | 1 | 2 |
_aA pharmaceutical study on aripiprazole / _cAly Ahmed Abdelbary ; Supervised Abdelhalim Elassasy , Mohamed Elnabarawi , Bhaskara Jasti |
| 246 | 1 | 5 | _aدراسة صيدلية على عقار الأريبيبرازول |
| 260 |
_aCairo : _bAly Ahmed Abdelbary , _c2011 |
||
| 300 |
_a224 P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceuties | ||
| 520 | _aNanomilling refers to an attrition process where the particle size of the drug is reduced down to the submicron range by media milling of the drug crystals in water - based stabilizer solution . These nanoformulations offer increased dissolution rates for drug compounds with poor aqueous solubility ( BCS class II and IV ) and consequently enhance their bioavailability | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aAripiprazole | |
| 653 | 4 | _aNanomilling | |
| 653 | 4 | _aNanosuspensions | |
| 700 | 0 |
_aAbdelhalim Elassasy , _eSupervisor |
|
| 700 | 0 |
_aBhaskara Jasti , _eSupervisor |
|
| 700 | 0 |
_aMohamed Elnabarawi , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aFatma _eCataloger |
||
| 905 |
_aNazla _eRevisor |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c37750 _d37750 |
||